title: Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
abstract: This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.
authors.forename: David S
authors.initials: DS
authors.lastname: Ettinger
authors.forename: Douglas E
authors.initials: DE
authors.lastname: Wood
authors.forename: Dara L
authors.initials: DL
authors.lastname: Aisner
authors.forename: Wallace
authors.initials: W
authors.lastname: Akerley
authors.forename: Jessica
authors.initials: J
authors.lastname: Bauman
authors.forename: Lucian R
authors.initials: LR
authors.lastname: Chirieac
authors.forename: Thomas A
authors.initials: TA
authors.lastname: D'Amico
authors.forename: Malcolm M
authors.initials: MM
authors.lastname: DeCamp
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Dilling
authors.forename: Michael
authors.initials: M
authors.lastname: Dobelbower
authors.forename: Robert C
authors.initials: RC
authors.lastname: Doebele
authors.forename: Ramaswamy
authors.initials: R
authors.lastname: Govindan
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Gubens
authors.forename: Mark
authors.initials: M
authors.lastname: Hennon
authors.forename: Leora
authors.initials: L
authors.lastname: Horn
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Komaki
authors.forename: Rudy P
authors.initials: RP
authors.lastname: Lackner
authors.forename: Michael
authors.initials: M
authors.lastname: Lanuti
authors.forename: Ticiana A
authors.initials: TA
authors.lastname: Leal
authors.forename: Leah J
authors.initials: LJ
authors.lastname: Leisch
authors.forename: Rogerio
authors.initials: R
authors.lastname: Lilenbaum
authors.forename: Jules
authors.initials: J
authors.lastname: Lin
authors.forename: Billy W
authors.initials: BW
authors.lastname: Loo
authors.forename: Renato
authors.initials: R
authors.lastname: Martins
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Otterson
authors.forename: Karen
authors.initials: K
authors.lastname: Reckamp
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Riely
authors.forename: Steven E
authors.initials: SE
authors.lastname: Schild
authors.forename: Theresa A
authors.initials: TA
authors.lastname: Shapiro
authors.forename: James
authors.initials: J
authors.lastname: Stevenson
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Swanson
authors.forename: Kurt
authors.initials: K
authors.lastname: Tauer
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Yang
authors.forename: Kristina
authors.initials: K
authors.lastname: Gregory
authors.forename: Miranda
authors.initials: M
authors.lastname: Hughes
mesh_terms: D015415:Biomarkers; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019468:Disease Management; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D011379:Prognosis; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers